![](https://www.iteostherapeutics.com/wp-content/uploads/2022/04/Dot.png)
One team: We work together to develop breakthrough therapies to treat cancer through improved immune response.
![two scientists at computer workstation in a lab](https://www.iteostherapeutics.com/wp-content/uploads/2022/04/scientists-workstation-about-us-1024x440.jpg)
Our two clinical-stage product candidates, EOS-448 and Inupadenant, each target a key mechanism that inhibits an effective antitumor immune response.
The ATP-adenosine pathway is recognized as a key pathway that modulates immune responses in pathological conditions. We designed Inupadenant to inhibit the ATP-adenosine pathway by specifically targeting A2AR, which is the primary adenosine receptor on immune cells with a high affinity for adenosine.
EOS-448 is an anti-TIGIT human immunoglobulin G1, or IgG1, antibody that we are developing to inhibit the immunosuppressive activity of TIGIT. TIGIT is a cell surface receptor expressed on multiple immune cells, including CD8+ T cells, natural killer, or NK, cells and T regulatory cells, or Tregs, a cell population that inhibits the immune response.